Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...

Shares of Syndax Pharmaceuticals have tumbled 17% after a phase 2 flop | Syndax and Incyte are cutting their idiopathic ...

Rather than another instance of on-shoring enthusiasm, ARPA-H’s personalized RNA drug production network project should be ...

UCB is encouraging people with immunology-driven diseases such as hidradenitis suppurativa (HS), plaque psoriasis and ...

Drug-device maker Kaléo has secured a federal contract worth $96.1 million, enlisting in an effort to bolster U.S. biodefense ...

One in two women is unaware that hormonal fluctuations during perimenopause and menopause can affect their skin, a Galderma ...

Roughly half a year after the close of its deal to acquire Bayer spinout AiCurus, Asahi Kasei’s $920 million bet has paid off ...

Less than four years after returning to Bausch + Lomb to lead the eye health company following its split from Bausch Health, ...

Life sciences organizations have invested heavily in data and analytics, yet timely decision making remains a challenge. | ...

Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...

All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where ...

With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...